Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Celgene (NASDAQ:CELG) said it expects 2007 adjusted diluted EPS to double to $1.05 and 2007 revenue to rise more
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury